• If you are wondering whether Phibro Animal Health's current share price reflects its real worth, you are not alone, many investors are asking the same question.
• The stock last closed at US$47.92, with returns of 16.9% over 30 days, 28.5% year to date and 105.4% over 1 year, while the past 3 and 5 years show returns of 237.6% and 121.2% respectively, along with a 12.2% decline over the last 7 days.
• Recent coverage around animal health, biosecurity and livestock productivity has kept attention on companies like Phibro Animal Health, as investors weigh long term demand for animal health products against changing farm economics. At the same time, the market has been tracking sector news around regulation, input costs and demand trends. These factors help frame how investors respond to short term price moves.
• On our valuation checks Phibro Animal Health has a score of 2 out of 6, which means the company screens as undervalued on 2 of 6 metrics. Next we will look at what the main valuation approaches say, before finishing with a broader framework that can help you put all these numbers in context.

Phibro Animal Health scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Phibro Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a business could generate in the future and discounts those back to what they might be worth in today's dollars. It is essentially asking what future cash flows are worth right now.

For Phibro Animal Health, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $42.28 million. Analysts supply free cash flow estimates for the first few years, and Simply Wall St then extrapolates further out, with projected free cash flow of $246.93 million in 2035 based on the provided path of estimates and extensions.

When those projected cash flows are discounted back using this model, the estimated intrinsic value for Phibro Animal Health is US$119.16 per share. Compared with the recent share price of US$47.92, the DCF output suggests the stock is about 59.8% below this intrinsic estimate. On this approach, the shares screen as undervalued relative to the model's intrinsic value estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Phibro Animal Health is undervalued by 59.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Phibro Animal Health Price vs Earnings

For a profitable business, the P/E ratio is a useful way to think about value, because it links what you pay directly to the earnings the company is already generating. A higher or lower P/E often reflects what the market is willing to pay for each dollar of profit.

What counts as a “normal” P/E really comes down to growth expectations and risk. Companies with stronger expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty typically points to a lower one.

Phibro Animal Health currently trades on a P/E of 21.09x. That is higher than the peer group average of 9.54x and slightly above the Pharmaceuticals industry average of 18.83x. Simply Wall St also calculates a proprietary “Fair Ratio” for Phibro of 18.58x, which reflects factors such as its earnings profile, industry, profit margins, market value and identified risks.

This Fair Ratio can be more informative than a simple comparison with peers, because it adjusts for company specific characteristics rather than assuming all firms in the group deserve the same multiple. Comparing Phibro’s current 21.09x P/E with the 18.58x Fair Ratio suggests the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Phibro Animal Health Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce Narratives, a simple tool on Simply Wall St's Community page that lets you spell out your story for Phibro Animal Health, link it to a forecast for revenue, earnings and margins, and see the fair value that falls out of those assumptions next to the live share price. This allows you to judge for yourself whether the company looks closer to the more bullish US$50 view or the more cautious US$27 view, with your Narrative automatically refreshing as new earnings, news or guidance are released.

For Phibro Animal Health, however, we will make it really easy for you with previews of two leading Phibro Animal Health Narratives:

Fair value: US$48.50 per share

Implied discount to this fair value: about 1.2% below the narrative fair value at the recent US$47.92 share price

Revenue growth input used in this narrative: 3.47% a year

• Analysts in this camp see Phibro Animal Health as capable of supporting a higher valuation if it delivers on expected revenue growth, margin expansion and earnings through to around 2028.
• The narrative leans on steady revenue growth, rising profit margins and a lower future P/E of 15.61x than today, while still assuming the business can support that multiple based on its earnings profile.
• On this view, the current price sits modestly below the US$48.50 fair value anchor, so the focus is on whether management can execute on guidance, manage risks around regulation and product mix, and keep earnings on the projected path.

Fair value: US$32.00 per share

Implied premium to this fair value: about 49.8% above the narrative fair value at the recent US$47.92 share price

Revenue growth input used in this narrative: 3.96% a year

• The more cautious narrative stresses long term pressure on traditional livestock markets from changing consumer habits, alternative proteins and tighter regulation of medicated feed additives.
• It assumes earnings growth and margin gains are possible, but only justify a lower future P/E of 11.53x, which pulls the fair value estimate down to US$32.00 despite revenue and profit growth assumptions.
• From this angle, today’s share price looks well ahead of the narrative fair value, so execution risk, regulatory shifts and competition are front and center for anyone weighing the downside case.

Put simply, the bullish narrative treats Phibro Animal Health as close to fairly valued with some room if execution holds, while the bearish narrative treats the current price as rich relative to its own fair value anchor. Reading both in full can help you decide which assumptions fit best with how you see the business and the animal health industry over the next few years.

Do you think there's more to the story for Phibro Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.